Agios to Present Clinical Data from its IDH Program at ASCO

World News: . []

CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that data from its isocitrate dehydrogenase (IDH) programs will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago.

The accepted abstracts are listed below and are available online on the ASCO conference website: http://abstracts.asco.org/.

More news and information about Agios Pharmaceuticals, Inc.

Published By:

Globe Newswire: 21:05 GMT Wednesday 15th May 2019

Published: .

Search for other references to "agios" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us